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Abstract
Background: The aim of the study was the assessment of the impact of the molecular genetic Xpert MTB/Rif assay on the diagnostic delay and the 
treatment effectiveness in pulmonary tuberculosis, according to the results of the microbiological and molecular-genetic methods, in order to optimize 
the management of the drug resistant tuberculosis.
Material and methods: A retrospective selective study, which included 226 patients with multidrug-resistant pulmonary tuberculosis (study sample) and 
78 patients with drug-susceptible pulmonary tuberculosis (control group), was performed. Patients were divided into 2 subgroups following the results 
of the molecular-genetic and bacteriological investigations. The study sample was divided in two groups: the 1st group included 85 patients enrolled in 
the treatment for drug resistant tuberculosis, according to the results of the Xpert MTB test and the 2nd group included 141 patients enrolled in the 
treatment DOTS plus, according to the results of the conventional cultures.
Results: The impact of the molecular genetic GeneXpert MTB/Rif assay was demonstrated on early diagnosis, adequate treatment according to the drug 
susceptibility to rifampicin, shorter duration of the treatment, low rate of the side events, optimal treatment compliance and higher treatment effectiveness. 
The conventional microbiological methods contributed to the late diagnosis of the patients, high rate of the severe and complicated tuberculosis, long 
duration of the treatment which were reflected on the low treatment effectiveness. However the conventional culture methods allowed the treatment 
individualization according to the drug susceptibility tests.
Conclusions: Target screening of the population with risks and compulsory investigation by GeneXpert MTB/Rif assay will diminish the rate of severe 
late detected forms of pulmonary tuberculosis and adapt the treatment according to the drug resistance to rifampicin.
Key words: MDR-TB, Xpert MTB/Rif assay, treatment.
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Introduction
Tuberculosis is one of the most important challenges for 
any health care system [15, 38, 42, 45]. The World Health 
Organization (WHO) declared tuberculosis a global emer-
gency in 1993. Actually the Republic of Moldova ranks 
among the 30 countries with the highest burden of multi-
drug-resistant tuberculosis (MDR-TB), defined as the in-
fection with resistant strains of Mycobacteria tuberculosis to 
at least two most powerful anti-tuberculosis drugs: isonia-
zid and rifampicin [45]. In 2001 the Republic of Moldova 
started the national implementation of the DOT (Directly 
Observed Treatment) strategy in the tuberculosis patient’s 
management recommended by the World Health Organi-
zation [10]. Its implementation determined the epidemic 
extension of primary drug-resistant infection in the popu-
lation. The rate of the primary MDR-TB, established as an 
infection with drug resistant strains increased four times 
in our country during the period 2003-2017 (6.0% – 2003, 
9.9% –2004, 13.4% – 2005, 19.4% – 2006, 17.8% – 2007, 
24.0% – 2008, 22.2% – 2009, 25.7% – 2010, 26.35% – 2011, 
24% – 2012, 25% – 2013, 25% – 2014) and acquired drug-
resistance two times (37.5% – 2003, 38% – 2004, 49.6% – 
2005,50.8 % –2006, 52.3% – 2007, 59.0% – 2008, 64.85% 
– 2009, 67.8% – 2010, 63.8% – 2011, 62% – 2012, 62% – 
2013, 63%– 2014) [10]. The extension of the drug resistance 
lowered the treatment effectiveness (2005 –  62%, 2006 – 
62%, 2007 – 62%, 2008 – 58%, 2009 – 57%, 2010 – 52%, 
2011 – 62%, 2012 – 62%, 2013 – 62%) which was lower in 
average by 20% compared with targeted 85% recommended 
by the WHO [4]. The low success rate was directly linked 
to the high rate of lost to follow-up patients: 2001 – 5,5%, 
2002 – 15,6%, 2003 – 10,5%, 2004 – 10,4%, 2005 – 10,9%, 
2006 – 11,7%, 2007 – 10,7%, 2008 – 7,4%, 2009 – 6,2%, 
2010 – 7,9%, 2011 – 7,7%, 2012 – 5,2% [5]. International 
researches established high rate of drug resistance among 
HIV co-infected patients, which lowers treatment outcome 
and endangers the epidemiological situation [35].  Between 
2011 and 2015 the rate of HIV infected among tuberculosis 
new cases patients increased by 2,6%: 2011 – 5,0%, 2012 – 
5,0%, 2013 – 2,2%, 2014 – 5,3%, 2015 – 7,6% in Chisinau 
and 2011 – 5,1%, 2012 – 5,1%, 2013 – 5,2%, 2014 – 6,5% 
and 2015 – 7,7% in the Republic of Moldova [5]. The rate of 
HIV infection in new and relapsed cases increased evidently 
in Chisinau by 2,3%: 2011 – 4,6%, 2012 – 4,4%, 2013 – 2,9%, 
2014 – 5,5% and 2015 – 6,9% and by 2,9% in the Republic 
of Moldova: 2011 – 5,2%, 2012 – 5,3%, 2013 – 5,9%, 2014 – 
7,2% and 2015 – 8,1% [5]. The rate of TB-HIV co-infected 
cases among died patients showed an increased dynamic in 
Chisinau by 4,2%: 2011 – 11,9%, 2012 – 13,8%, 2013 – 9,2%, 
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2014 – 16,0% and 2015 – 16,1% as well as in the entire coun-
try by 5,3%: 2011 – 15,4%, 2012 – 12,8%, 2013 – 11,8%, 2014 
– 20,8% and 2015 – 20,7% [5].
The diagnosis of MDR-TB, especially in children and 
HIV co-infected patients represents an important concern 
in many countries [12, 35, 36, 46]. No much technology 
is available for an accurate detection of the drug resistant 
strains of Mycobacteria tuberculosis worldwide [29]. So, 
detected deficiencies represent a major obstacle in the im-
provement of tuberculosis control and reduction of the 
global burden [11]. Microscopy alone, although inexpen-
sive, misses one of three patients and detects only those with 
relatively advanced disease and severe lung destruction [8, 
10, 32]. 
Only 28% of Moldovan patients were reported as smear 
positive cases in 2016 [5]. So, misdiagnosed cases increase 
the risk of infection transmission in the healthy population, 
endangering tuberculosis control at the regional level [11]. 
In the countries with a high burden of the HIV infection, 
the sensitivity of the smear microscopy is very low, which 
contributed to the increasing use of the rapid methods in 
the diagnosis of tuberculosis [35, 36]. According to the latest 
researches substantial efforts were made for strengthening 
the laboratory capacities for the diagnosis of smear-negative 
cases, TB-HIV co-infected cases and MDR-TB cases [10]. 
Conventional methods, such as smear microscopy, liq-
uid and solid culture methods require qualified laboratories 
with important consequences: delayed diagnosis, worsen-
ing of the patient’s condition, inadequate treatment which 
can generate additional drug resistance and continuous 
transmission of infection in the society [33]. In 2010 world-
wide were implemented the first – and second – line probe 
tests which require extensive laboratory infrastructure and 
should be performed only in the reference facilities [33]. 
Starting from 2014 a real-time polymerase chain reaction 
Xpert MTB/RIF test for the Mycobacterium tuberculosis gene 
and the rPob gene mutation detection were implemented in 
the Republic of Moldova [8]. The Xpert MTB/RIF platform 
was developed by the Cepheid Company (Sunnyvale, USA). 
More than 50 devices and 12.000 cartridges were distrib-
uted in the Moldovan civilian specialized services, 2 in the 
penitentiary services and 2 in AIDS services. It contributed 
to an early detection of tuberculosis, precocious treatment, 
according to the rifampicin sensitivity, improvement of the 
infection control, increasing the treatment success rate, 
which are considered the most efficient tools for interrupt-
ing the epidemiological chain. [11]. Actual WHO recom-
mendation regarding the Xpert MTB/RIF is to test all adults 
and children presumed to have pulmonary tuberculosis, 
with or without HIV co-infection. In addition, WHO es-
tablished conditional recommendations to test extrarespira-
tory specimens of the adults and children presumed to have 
extrapulmonary tuberculosis [46]. The interpretation of the 
test results must be correlated with laboratory and clinical 
findings [9]. Published data established a high sensitivity 
of the Xpert MTB/RIF among culture positive specimens, 
in an average 97.3% and among smear positive patients – 
99.5% [6]. The sensitivity of the Xpert MTB/RIF is slight-
ly decreased in a single sputum sample [7]. Assessing the 
threshold of the estimated sensitivity it was demonstrated 
that the biological sample must contain at least 131 colony 
forming units (CFU) per ml of sample with a confidence 
interval ranging from 106.2 CFU to 176.4 CFU [6]. The 
sensitivity depends on the collection procedure, storage, 
transportation and technical errors. Insufficient volume of 
the specimen and insufficient concentration of the viable or-
ganisms are the most frequent causes of the negative results 
[9]. The test specificity compared with the non-tuberculosis 
patients are also high – 97.9% [6]. Despite of the higher 
sensitivity of the Xpert MTB/RIF test, more than one half 
of Moldovan patients were diagnosed through the clinical-
radiological methods in 2016 [4]. Due to the low cost of the 
Lowenstein Jenson and BACTEC cultures, conventional 
methods remain the golden standard for Mycobacterum tu-
berculosis complex detection and drug susceptibility testing 
on the national standards, instead of highly recommended 
Xpert MTB/RIF test [10].
The standard treatment for drug-susceptible tuberculo-
sis, according to WHO recommendations in the Republic of 
Moldova has been used since 2000 as a part of DOT strategy 
and lasts 6 months in new cases and 8 months in previously 
treated cases [11]. The treatment of the new drug-suscep-
tible patients consists in a two phase regimen with four 
first-line anti-tuberculosis drugs: Isoniazid (H), Rifampicin 
(R), Ethambutol (E) and Pyrazinamide (Z) in the intensive 
phase and two drugs H and R in the continuation phase 
[39]. A regimen of eight months consisted of H, R, E, Z and 
Streptomycin (S) during the intensive phase and H, R and E 
in the continuation phase is used for the treatment of previ-
ously treated cases (relapses, failed and treatment for lost to 
follow-up cases) [39]. Multidrug-resistant patients are treat-
ed using the standard regimen for resistant tuberculosis that 
consists of second-line anti-tuberculosis drugs during 18-
24 months [47]. Second-line anti-tuberculosis drugs used 
in the treatment of drug resistant tuberculosis are: Fluoro-
quinolones, Aminoglycosides, Thioamides, Oxazolidinones 
and new drugs such as Delamanid and Betaquiline. The 
major contributing factor of the treatment effectiveness rep-
resents the right combination of the drugs, according to the 
Mycobacteria susceptibility results [40]. Without an appro-
priate treatment tuberculosis-related death occurs in aver-
age within 2 years [24]. Due to high global epidemiological 
burden tuberculosis was placed on the 5th place in the top of 
the causes of death [45]. 
The major social determinants of tuberculosis and poor 
outcome are: social and economic inequalities, high lev-
els of internal/external migration, rapid urbanization and 
population growth in urban areas [22, 25, 27]. Such deter-
minants determine the polarization of the public health in-
terventions, poor housing, low environmental conditions, 
malnutrition, geographic and cultural barriers in access 
to the health care [47]. There are several predictive factors 
for low treatment effectiveness. First of all – the infection 
with drug resistant and virulent mycobacteria [47]. The risk 
depends on the spread of the virulent mycobacteria in the 
community. The second group includes the factors which 
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increase the disease relapse or recrudescence of the latent 
tuberculosis infection: phtisiogenic ages (infants less than 
5 years, teenagers, elders aged 65 and more), malnutrition, 
comorbid state and lack of the BCG vaccination [11]. The 
third group included the determinants of the patient’s im-
mune status: HIV infection, immune suppressive drugs 
(>15mg/day of prednisone for 1 month or more, immune 
modulators: TNF-α blockers or oral steroids, antineoplastic 
agents), diabetes, cancer, silicosis, chronic respiratory dis-
eases, gastrointestinal diseases, underweight, phtysiogenic 
ages, harmful habits (tobacco smoking, alcohol abuse, illicit 
drug using) [27]. The fourth group includes: the accessibili-
ty of the sick people to the tuberculosis screening and health 
care, treatment compliance and patient’s nursing [44]. In 
this group are also included social related barriers: lack of 
the social protection and medical insurance, geographic and 
economic barriers, cultural behaviour or stigma. The social 
determinants of the poor treatment outcome are strongly 
correlated with the psychotropic substance abuse: tobacco 
smoking, alcohol abuse and illicit drug using. Such behav-
iour habits contribute to multiple treatment interruptions 
and high rate of death. 
Low treatment adherence and high rate of the lost to fol-
low-up patients contributed to the development of a shorter 
conventional MDR-TB regimen lasting less than 12 months 
with low costs (<1.000$/patient) [47]. It showed promising 
results in selected MDR-TB patients and WHO updated its 
treatment guidelines in 2016 by including the recommenda-
tion to use the shorter MDR-TB regimen in patients with 
non-complicated tuberculosis (excluding extrapulmonary 
tuberculosis and pregnancy) [47]. Fluoroquinolones and 
Aminoglycosides are key drugs in the new MDR-TB regi-
men, however, surveillance of the cross resistance in five 
high burden countries: Azerbaijan, Bangladesh, Belarus, 
Pakistan and South Africa established that resistance of Ri-
fampicin is frequently associated with resistance to Pyrazin-
amide, so the effectiveness of the short regimen might be 
lower than predicted [45]. Considering the WHO recom-
mendations for aligning the Moldovan procedures for the 
international quality-assured standards, it was established 
the importance of the diagnosis algorithm improvement for 
increasing the treatment effectiveness. 
The aim of the study consisted in the comparative as-
sessment of the clinical aspects and the treatment effective-
ness in patients with pulmonary tuberculosis diagnosed ac-
cording to the results of the conventional microbiological 
methods (solid either liquid media) and molecular-genetic 
method Xpert MTB/RIF test (susceptible or resistant to Ri-
fampicin forms). 
Material and methods
A selective, descriptive and retrospective study was 
conducted according to a linear model, structured in sev-
eral stages: purpose, sampling, investigation, data collection 
and interpretation. A preliminary documented research has 
been carried out on new cases of pulmonary tuberculosis 
investigated and treated in the Clinical Hospital of Phtisio-
pneumology of Chişinău between 2010 and 2014. The inves-
tigation methods were used according to the National Clini-
cal Protocol. The patients were investigated by laboratory 
examinations: general blood and urine analysis, chest X-ray, 
sputum microscopy for acid fast bacilli, conventional mi-
crobiological investigations (smear microscopy, Lowenstein 
– Jensen culture, BACTEC assay) and innovative platform 
of the Xpert MTB/RIF test. The statistical processing of the 
results was done computerized through the Excel program 
of the Microsoft Office package. For estimating significant 
differences, the Student test was used (differences were true 
for p<0.05; P – characteristic rate, ES – standard error).
Results and discussion
The study included 304 patients with pulmonary tuber-
culosis, of which 141 had proved multidrug-resistant tuber-
culosis (MDR-TB), according to the conventional drug sus-
ceptibility tests, 85 had Rifamipicin resistance on the Xpert 
MTB/RIF test and 78 patients were Rifamipicin susceptible 
of the Xpert MTB/RIF test. Distributing patients in groups 
according to the drug susceptibility definition, 226 were di-
agnosed with MDR-TB and 78 with sensible tuberculosis. 
The patients were divided into three groups according to the 
results of the molecular-genetic or bacteriological investiga-
tions: in the first group were included 85 patients enrolled in 
the DOTS plus cohort treated for MDR-TB according to the 
results of the Xpert MTB test and the second group included 
141 patients treated for MDR-TB, according to the results of 
the drug susceptibility test on conventional microbiologi-
cal methods (Lowenstein – Jensen culture, BACTEC assay). 
Both groups should be considered as a study sample con-
stituted from 226 patients with MDR-TB. The third group, 
defined as the control group, included 78 patients with posi-
tive and sensible for Rifampicin Xpert MTB/RIF test and 
diagnosed with drug susceptible tuberculosis. 
Assessing the groups according to the sex distribution 
was established the predominance of men in all groups. So, 
in the fist group there were 61 men (71.7%) and 24women 
(28.3%) cases with a male/female ratio = 2.5/1. In the second 
group men were more frequently identified than women 
and their rate was higher compared with the first group: 106 
(75.1%) vs 35 (24.8%) women with male/female ratio=3/1. 
In the third (control group) there were 53 men (68%) cases 
and 25 women (32%) cases with a male/female ratio=2.1/1. 
The urban residence prevailed in all three groups compared 
with the rural one. So, in the first group there were 67 urban 
residents (78.8%), in the second group – 90 (70.2%) and in 
the third group – 60 (76.9%). Assessing the social vulnera-
bility it was established that poor living conditions prevailed 
in the MDR-TB sample. In the first group there were 69 
(81.2%) socially vulnerable patients, in the second group – 
102 (81.2%), and only 28 (35.9%) patients in the third group. 
The rate of the unemployed patients was high in the first and 
second groups, 64 (75.3%) and 104 (73.7%) compared with 
the third group 47 (60.3%) patients. Unqualified workers 
were in a similar proportion in the first and second groups, 
23 (27.1%) and 25 (24.1%) and higher compared with the 
third group 14 (17.9%) patients. Assessing the level of the 
school education it was established that completed general 
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studies presented a similar proportion of patients in the first 
and second groups 34 (40.1%) and 51 (36.2%) being higher 
compared with the third group of 14 (17.9%) patients. The 
professional studies prevailed in the third group – 39 (50.1%) 
compared with the first and second groups, 24 (28.2%) and 
39 (27.7%) patients. Comparing the rate of patients with a 
low school education, which included graduated primary 
school, incomplete general school and secondary school it 
was determined their predomination in the first and second 
groups compared with the third group. The high level of the 
school education which included professional and superior 
studies predominated in the third group compared with the 
first and second groups. The civil status of the single state 
person prevailed in the first group 37 (43.5%) compared with 
the second and third groups, 36 (25.5%) and 26 (33,3%) pa-
tients. Married patients predominated in the second group 
105 (74.5%) compared with the first and third groups, 48 
(56.5%) and 52 (66.7%) patients. Lack of the health insur-
ance predominated in the third group 43 (55.1%) compared 
with the first and second groups, 43 (50.6%) and 92 (65.2%) 
patients. Comparing the groups of patients was established 
a more evident social vulnerability of the MDR-TB patients 
from the study sample being appreciated through the rate of 
the unemployed persons, unqualified workers, patients with 
low level of the school education and lack of the health insur-
ance (tab. 1).
Table 1




1st group 2nd group 3rd group p1/2 p1/3 p2/3
n=85(P%) n=141(P%) n=78(P%)
Employed 21 (24,7) 37 (26,3) 31 (39,7) >0,05 <0,05 <0,05
Unemployed 64 (75,3) 104 (73,7) 47 (60,3) >0,05 <0,05 <0,05
Low level of 
education
53 (62,3) 92 (65,5) 23 (29,5) >0,05 <0,05 <0,05
Optimal level 35 (37,7) 49 (34,5) 55 (70,5) >0,05 <0,05 <0,05
Single civil 
state
37 (43,5) 36 (25,5) 26 (33,3) >0,05 >0,05 >0,05
Married/ in 
couple
48 (56,5) 105 (74,5) 52 (66,7) >0,05 >0,05 >0,05
Epidemiological risk factor, established during the 
household contact with a sick family member was identi-
fied in a similar proportion in the second and third groups, 
68 (48.2%) and 39 (50.1%) compared with the first group, 
25 (29.4%) patients. Migrants were identified in a higher 
proportion in the third group 12 (15.4%), compared with 
the first and second groups 10 (11.8%) and 14 (9.9%) pa-
tients. Former detainees were more numerous in the second 
group 28 (19.9%) compared with the first and third groups 
13 (15.3%) and 11 (14.1%) patients. Harmful habits were 
detected in a high proportion in all groups. So, the active 
smoking prevailed in the second group 117 (83.1%) com-
pared with the first group and third group 63 (74.1%) and 
48 (61.5%) patients. Alcohol abusers prevailed in the second 
group 81 (57.4%) compared with the first group and third 
groups 38 (44.7%) and 32 (41.1%) patients. A limited num-
ber of drug users were diagnosed in all groups: 4 (4.7%) in the 
first group, 3 (2.4%) in the second group and 1 (1.3%) in the 
third group. Patients that form risk groups were distributed 
differently among selected samples. Even statistical differ-
ence was not established, contact with a sick family member 
predominated in the groups diagnosed with drug susceptible 
tuberculosis through the Xpert MTB/RIF and MDR-TB by 
conventional methods. No differences were established re-
garding harmful habits in the studied groups (tab. 2).
Table 2
Distribution of patients in risk groups
Risk 
groups
1st group 2nd group 3rd group 






TB contact 25(29,4) 68(48,2) 39(50) <0,05 <0,05 >0,05
Migrants 10 (11,8) 14 (9,9) 12 (15,4) >0,05 >0,05 >0,05
Former 
detainees
13 (15,3) 28 (19,9) 11 (14,1) >0,05 >0,05 >0,05
Smokers 63 (74,1) 117 (83) 48 (61,5) >0,05 <0,05 <0,05
Alcohol 
abuse
38 (44,7) 81 (57,4) 32 (41) >0,05 >0,05 <0,05
Chronic  
alchoolism
9 (10,6) 17 (12,1) 0 >0,05 <0,05 <0,05
DIU 4 (4,7±2,3) 3 (2,1±1,2) 1 (1,3±1,3) >0,05 >0,05 >0,05
Note: DIU – drug injection use;
Assessing the associated diseases, it was established 
that the comorbid state predominated in the first group 69 
(81.1%) compared with the second and third groups, 69 
(48.9%) and 58 (74.3%) patients. Distributing patients, ac-
cording to the nosological groups of the associated diseases 
was determined the predomination of the gastrointestinal 
disorders in the first group 36 (42.4%), followed by the sec-
ond and third groups, 45 (31.9%) and 28 (35.9%) patients. 
Chronic respiratory diseases were diagnosed in a similar 
proportion in all groups: 31 (36.5%) in the first group, 39 
(27.7%) in the second group and 35 (44.9%) patients in 
the third group. Diabetes mellitus was diagnosed more fre-
quently in the first group 12 (14.1%) followed by the third 
and the second groups 9 (11.5%) and 7 (5.1%) patients. Co-
infected TB/HIV has been encounted frequently in the first 
group 4 (4.7%) followed by the third group 2 (2.7%) and 1 
(0.7%) patient in the second one. 
Detected particularities established the predominance 
of the passive case-finding in the first and second groups, 
68 (80.1%) and 106 (75.2%) patients compared with 38 
(49.7%) patients in the third group. Active screening of the 
risk groups was most frequently used to detect patients in 
the third group 40 (51.3%) compared with 17 (20.1%) and 
35 (24.8%) patients from the first and second groups. Dis-
tributing patients according, to the diagnostic delay, it was 
identified that each fourth patient in the first and second 
group were diagnosed in more than three months after the 
disease onset. The early diagnosis till 30 days after the dis-
ease onset was established in each fifth patient in the third 
group 7 (18.4%). Pulmonary infiltrative tuberculosis was 
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diagnosed in most of the patients in all groups: 79 (93.1%) 
in the first group, 132 (93.6%) in the second group and 72 
(92.3%) patients in the third group. Severe forms in terms 
of disseminated and fibro-cavitary tuberculosis were diag-
nosed in a similar proportion in all groups: 6 (7.1%) in the 
first group, 7 (4.9%) in the second group and 6 (7.7%) in the 
third group. Complicated tuberculosis was diagnosed in a 
similar proportion in the first group and third groups, 28 
(32.9%) and 24 (30.7%) patients, compared with 24 (17.1%) 
patients of the second group. Among complications pre-
dominated pleurisy in a similar proportion in all groups: 14 
(16.5%) in the first group, 21 (14.9%) in the second group 
and 9 (11.5%) patients in the third group. Hemoptysis pre-
dominated in the second group 25 (17.8%), followed by the 
first and third groups 9 (10.6%) and 9 (11.6%) patients. The 
most severe complication defined as tuberculosis meningi-
tis was diagnosed in 3 (1.4%) patients of the second group. 
No such complication was diagnosed in other groups. Lung 
parenchyma destruction predominated in the second group 
137 (97.2%), followed by a similar proportion in the first and 
third groups, 67 (78.9%) and 58 (74.4%) patients. More than 
three pulmonary segments were affected by tuberculosis in 
the majority of patients from all groups: 80 (94.1%) in the 
first group, 127 (90.1%) in the second group and 48 (61.5%) 
patients in the third group. Both lungs were involved in 
two thirds of the first and second groups, 74 (87.1%) and 
124 (87.9%) and in each second patient of the third group 
– 51 (65.4%) cases. So, passive way of finding of symptom-
atic cases predominated in the MDR-TB sample and active 
screening of the risk groups in the drug susceptible sample. 
Even the pulmonary infiltrative tuberculosis was diagnosed 
in most of the cases, severe forms, involvement of both 
lungs and complicated tuberculosis were more frequently 
diagnosed in the sample diagnosed by microbiological con-
ventional methods.
Microscopic smear positive was more frequently dis-
tinguished in patients from the second group 96 (68.1%), 
followed by the first and third groups, 53 (62.3%) and 51 
(66.7%) patients. The delay between the diagnosis by Xpert/
RIF examination and the beginnig of the treatment was less 
than 10 days in the first and third groups. In one third of the 
second group the delay between culture examination and 
initiation of the treatment, according to the drug suscepti-
bility test constituted in average 2 months, however, in 3 till 
5 months the therapy was started in 64 (45.4%) patients and 
more than 5 months in 46 (32.6%) patients. Each second 
patient from the study sample with MDR-TB was identi-
fied resistant against all first-line anti-TB drugs: Isoniazid, 
Rifampicin, Ethambutol and Streptomycine: 40 (47.1%) in 
the first group and 67 (47.5%) patients in the second group. 
No drug resistant patients were diagnosed by culture meth-
ods in the third group, which confirmed the high specificity 
of the Xpert/RIF test. Sputum conversion under the anti-
tuberculosis treatment assessed by microscopic method 
during the first three months of the treatment for MDR-TB 
(DOTS-Plus) was distinguished in a higher proportion in 
the first group compared with the second group: 31 (58.5%) 
vs 21 (21.2%) patients. In most of the cases with drug sus-
ceptible tuberculosis included in the third group, 43 (84.2%) 
patients, the sputum conversion was obtained in the first 
three months. Sputum conversion during the first three 
months of the treatment assessed by culture methods was 
determined in the highest proportion in the third group, 
68 (87.2%) patients. In a lower proportion was established 
the sputum conversion in patients from MDR-TB groups. 
Comparing the first with the second group, the sputum con-
version predominated in the first group 55 (64.8%) vs. 30 
(21.3%) patients from the second group. A high proportion 
of the non-assessed patients, which included died and lost 
to follow-up patients were established in the second group, 
due to delayed diagnosis and longer duration of the treat-
ment compared with the first group (tab. 3).
Table 3
Conversion of sputum by culture methods
Sputum conversion
1st group 2nd group
p
n=85 (P%) n=141 (P%)
Till 3 months 55 (64.8) 30 (21.3) <0,001
3-6 months 39 (45.5) 64 (54.7) <0,05
6-12 months 2 (2.4) 13 (4.7) >0,05
More than 12 months 0 1 (0.7) >0,05
Non-assessed patients 9 (10.6) 45 (31.9) >0,05
Obtained data confirmed the impact of molecular ge-
netic test for early diagnosis, interruption of the epidemio-
logical chain and the appropriate treatment according to the 
drug resistance against Rifampicin. The early sputum con-
version assessed through the microscope and conventional 
culture methods had a high relevance in groups diagnosed 
by the Xpert MTB/RIF assay. It was due to a lower rate of se-
vere forms, lung destruction and an appropriate treatment, 
according to the drug resistance test to Rifampicin.
The anti-tuberculosis treatment duration in the first 
group was 24 months in 54 (63.52%) patients and 18 
months in 16 (18.8%) patients. A limited number were 
treated less than 6 months due to a precocious death. So, 
the Xpert MTB/RIF assay offers the opportunity of an early 
diagnosis and rapid begining of the appropriate treatment 
for drug resistant tuberculosis. In the second group the du-
ration of the anti-tuberculosis treatment was long due to 
a high rate of patients with severe and complicated tuber-
culosis. So, during 24 months were treated 37 (62.2%) and 
more than 24 months 76 (53.9%) patients. Treatment in out-
patient settings was performed by the every third patient in 
the first and third groups, 27 (31.8%) and 26 (33.1%) cases. 
First-line anti-tuberculosis drugs received all patients with 
drug susceptible tuberculosis from the third group. A few 
patients from the first and second groups were treated for a 
limited duration with first-line therapy till obtaining the re-
sults of the drug susceptibility test. The standard treatment 
for MDR-TB was initiated in the first and second groups 
83 (97.6%) and 113 (80.1%). However, in every fifth patient 
of the second group it was individualized according to the 
drug resistant susceptibility obtained through the conven-
tional culture methods. Data are shown in the table 4.
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Table 4
Anti-tuberculosis treatment duration in patients from 
the study sample
Duration 
1st group 2nd group
P
n= 85 (P%) n=141 (P%)
6 months 7 (8,2) 14 (9,9) >0,05
18 months 16 (18,8) 21 (14,9) >0,05
24 months 54 (63,5) 37 (26,2) <0,001
24-30 months 2 (2,3) 74 (52,5) <0,001
>30 months 0 2 (1,4) >0,05
Multiple treatment interruptions were established more 
frequently in the second group 42 (29.9%) followed by the 
first and third groups 18 (21.2%) and 8 (10.3%) patients. So, 
it was assessed that long treatment duration diminished the 
treatment compliance of patients with MDR-TB patients, 
especially those diagnosed through the conventional micro-
biological methods. Major adverse drug events were diag-
nosed in every third patient of the second group 43 (30.5%), 
followed by the first group and third group 19 (22.4%) and 
4 (5.1%) patients. Treatment success more frequently was 
established in the third group 67 (85.9%), followed by the 
first group 59 (69.4%) and second group 84 (59.6%).  Were 
lost to follow-up more frequently patients from the second 
group 21 (14.9%) which was due to multiple treatment in-
terruptions. The rate of patients lost to follow-up in the first 
and third groups was similar, 9 (10.7%) and 8 (10.3%). Died 
more frequently in the second group 22 (15.6%), followed by 
the first group 12 (14.1%) and the third group 1 (1.3%). So, 
the highest rate of lost to follow-up patients was explained 
by the long treatment duration and the higher death rates 
due to severe tuberculosis and high rate of major adverse 
drug events. Exposed data are presented in the table 5.
Table 5
Anti-tuberculosis treatment outcome in the study 
sample
Treatment outcomes 1st group 2nd group p
n= 85 (P%) n=141 (P%)
Treatment success 59 (69,4) 84 (59,6) >0,05
Including cured 54(63,5) 82(58,1) >0,05
Including completed the 
treatment
5(5,9) 2(1,4) >0,05
Treatment failure 5(5,9) 14(9,9) >0,05
Lost to follow-up 9(10,6) 21(14,9) >0,05
Died 12(14,1) 22(15,6) >0,05
Assessing all related data it was established the pre-
dominance of men in all selected groups, which confirmed 
their social vulnerability. Urban residence identified in two 
thirds of each group established that the level of the epide-
miological control is lower in cities. The social vulnerability 
was higher in the MDR-TB patients than in drug susceptible 
cases, demonstrated by the rate of the unemployed persons, 
with the lack of the social and medical insurance. Epidemio-
logical risk in terms of the tuberculosis contact was more rel-
evant in patients with drug resistant tuberculosis. Such risk 
conditions as migration, former detention, and harmful hab-
its had no prevalence in drug resistant or susceptible groups. 
Passive finding of the symptomatic cases predominated in 
the MDR-TB sample and active screening in the drug sus-
ceptible sample. Pulmonary infiltrative tuberculosis was di-
agnosed in most of the cases, but severe forms, involvement 
of both lungs and complicated tuberculosis were more fre-
quently identified in the sample diagnosed by microbiologi-
cal conventional methods. Early diagnosis, infection control 
and the adequate treatment according to the drug suscepti-
bility to Rifampicin were possible in the groups diagnosed by 
the Xpert MTB/RIF assay. It permitted the sputum conver-
sion in the first three months in most of the patients. Patients 
diagnosed through culture methods had more frequently 
extended radiological processes, both lungs involvement, 
which contributed to a long duration of treatment, high 
rate of the adverse drug events and low treatment outcome. 
The treatment success rate for drug susceptible tuberculosis 
reached the WHO recommended level 85%. The treatment 
success level for drug-resistant tuberculosis was low, mostly 
in the group diagnosed through the conventional microbio-
logical methods. Long duration till the sputum conversion of 
patients treated for drug resistant tuberculosis demonstrated 
their epidemiological burden on the healthy population. The 
low rate of the lost to follow-up patients and died due to the 
progression of pulmonary tuberculosis in groups diagnosed 
through the Xpert MTB/RIF assay was due to a shorter pe-
riod of the anti-tuberculosis treatment.
Conclusions
The molecular genetic Xpert MTB/Rif assay demonstrat-
ed an important impact on the diagnosis of pulmonary tu-
berculosis in terms of earlier diagnosis, adequate treatment 
according to the drug resistance to Rifampicin, shorter du-
ration of the treatment, low rate of the side events, optimal 
compliance and higher treatment effectiveness.
The conventional microbiological methods contributed 
to the late diagnosis of the patients, high rate of the severe 
and complicated tuberculosis and long duration of the treat-
ment which were reflected on the low treatment effective-
ness. However, the conventional culture methods allowed 
the individualization of the treatment, according to the drug 
susceptibility tests.
Target screening of the population with risks and com-
pulsory investigation by Xpert MTB/Rif assay will diminish 
the rate of severe late detected forms of pulmonary tuber-
culosis and adapt the treatment according to the drug resis-
tance to Rifampicin.
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